Perioperative β-blocker use: what is new in 2020?
Adrenergic beta-Antagonists
/ adverse effects
Anesthesiology
/ methods
Bradycardia
/ chemically induced
Cardiovascular Diseases
/ chemically induced
Humans
Hypotension
/ chemically induced
Intraoperative Care
/ methods
Myocardial Infarction
/ chemically induced
Perioperative Care
Perioperative Period
Postoperative Complications
/ chemically induced
Risk Factors
Stroke
/ chemically induced
Journal
Current opinion in anaesthesiology
ISSN: 1473-6500
Titre abrégé: Curr Opin Anaesthesiol
Pays: United States
ID NLM: 8813436
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
pubmed:
24
4
2020
medline:
26
6
2020
entrez:
24
4
2020
Statut:
ppublish
Résumé
Although the indications for β-blockers in the management of patients with congestive heart failure and myocardial infarction are well established, the use of β-blockers in the perioperative setting remains controversial. Since 2008 PeriOperative ISchemic Evaluation Trial, there have been numerous studies suggesting that perioperative β-blockers are associated with adverse events such as hypotension, bradycardia, increased mortality, and stroke. In this article, we review the most recent evidence to suggest an approach to perioperative β-blocker use tailored to patient and surgical risk factors. We also review recent studies on off-label uses for perioperative β-blockers.
Identifiants
pubmed: 32324663
doi: 10.1097/ACO.0000000000000853
pii: 00001503-202006000-00025
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
417-422Références
Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371:1839–1847.
Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol 2002; 39:542–553.
Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 2007; 50:e159–e241.
Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2014; 64:e77–e137.
Bemenderfer TB, Rozario NL, Moore CG, Karunakar MA. Morbidity and mortality in elective total hip arthroplasty following surgical care improvement project guidelines. J Arthroplasty 2017; 32:2359–2362.
Kertai MD, Cooter M, Pollard RJ, et al. Is compliance with Surgical Care Improvement Project Cardiac (SCIP-Card-2) measures for perioperative β-blockers associated with reduced incidence of mortality and cardiovascular-related critical quality indicators after noncardiac surgery? Anesth Analg 2018; 126:1829–1838.
Jørgensen ME, Hlatky MA, Kober L, et al. β-Blocker-associated risks in patients with uncomplicated hypertension undergoing noncardiac surgery. JAMA Intern Med 2015; 175:1923–1931.
Richman JS, Graham LA, DeRussy A, et al. Perioperative beta blockers and statins for noncardiac surgery patients with coronary stents. Am J Surg 2017; 214:180–185.
Venkatesan S, Jorgensen ME, Manning HJ, et al. Preoperative chronic beta-blocker prescription in elderly patients as a risk factor for postoperative mortality stratified by preoperative blood pressure: a cohort study. Br J Anaesth 2019; 123:118–125.
Shannon AH, Mehaffey JH, Cullen JM, et al. Preoperative beta blockade is associated with increased rates of 30-day major adverse cardiac events in critical limb ischemia patients undergoing infrainguinal revascularization. J Vasc Surg 2019; 69:1167–1172.e1.
Chan W, Kingwell BA, Schneider HG, et al. Preoperative biomarker evaluation for the prediction of cardiovascular events after major vascular surgery. J Vasc Surg 2019; 70:1564–1575.
Friedell ML, Van Way CW, Freyberg RW, Almenoff PL. β-Blockade and operative mortality in noncardiac surgery: harmful or helpful? JAMA Surg 2015; 150:658–663.
Andersson C, Mérie C, Jørgensen M, et al. Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a danish nationwide cohort study. JAMA Intern Med 2014; 174:336–344.
Park J, Kim J, Kwon JH, et al. Association between perioperative beta-blocker use and clinical outcome of noncardiac surgery in coronary revascularized patients without severe ventricular dysfunction or heart failure. PLoS One 2018; 13:e0201311.
Flu WJ, van Kuijk JP, Chonchol M, et al. Timing of preoperative beta-blocker treatment in vascular surgery patients: influence on postoperative outcome. J Am Coll Cardiol 2010; 56:1922–1929.
Wijeysundera DN, Beattie WS, Wijeysundera HC, et al. Duration of preoperative beta-blockade and outcomes after major elective noncardiac surgery. Can J Cardiol 2014; 30:217–223.
Wijeysundera DN, Duncan D, Nkonde-Price C, et al. Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2014; 64:2406–2425.
Bouri S, Shun-Shin MJ, Cole GD, et al. Meta-analysis of secure randomised controlled trials of beta-blockade to prevent perioperative death in non-cardiac surgery. Heart 2014; 100:456–464.
Chen RJ, Chu H, Tsai LW. Impact of beta-blocker initiation timing on mortality risk in patients with diabetes mellitus undergoing noncardiac surgery: a nationwide population-based cohort study. J Am Heart Assoc 2017; 6:pii: e004392doi: 10.1161/JAHA.116.004392.
doi: 10.1161/jaha.116.004392
Beattie WS, Wijeysundera DN, Karkouti K, et al. Does tight heart rate control improve beta-blocker efficacy? An updated analysis of the noncardiac surgical randomized trials. Anesth Analg 2008; 106:1039–1048.
Wallace AW, Au S, Cason BA. Perioperative β-blockade: atenolol is associated with reduced mortality when compared to metoprolol. Anesthesiology 2011; 114:824–836.
van Klei WA. Which is the preferred perioperative beta-blocker? Ned Tijdschr Geneeskd 2015; 159:A9798.
Jørgensen ME, Sanders RD, Køber L, et al. Beta-blocker subtype and risks of perioperative adverse events following noncardiac surgery: a nationwide cohort study. Eur Heart J 2017; 38:2421–2428.
Ollila A, Vikatmaa L, Sund R, et al. Efficacy and safety of intravenous esmolol for cardiac protection in noncardiac surgery. A systematic review and meta-analysis. Ann Med 2019; 51:17–27.
Bangalore S, Wetterslev J, Pranesh SS, et al. Perioperative beta blockers in patients having noncardiac surgery: a meta-analysis. Lancet 2008; 372:1962–1976.
Mashour GA, Sharifpour M, Freundlich RE, et al. Perioperative metoprolol and risk of stroke after noncardiac surgery. Anesthesiology 2013; 119:1340–1346.
Ashes C, Judelman S, Wijeysundera DN, et al. Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. Anesthesiology 2013; 119:777–787.
Blessberger H, Kammler J, Domanovits H, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev 2018; 3:CD004476.
Blessberger H, Lewis SR, Pritchard MW, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing noncardiac surgery. Cochrane Database Syst Rev 2019; 9:CD013438.
Obeid T, Arhuidese I, Gaidry A, et al. Beta-blocker use is associated with lower stroke and death after carotid artery stenting. J Vasc Surg 2016; 63:363–369.
Shaashua L, Shabat-Simon M, Haldar R, et al. Perioperative COX-2 and beta-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a Phase-II Randomized Trial. Clin Cancer Res 2017; 23:4651–4661.
Jang HI, Lim SH, Lee YY, et al. Perioperative administration of propranolol to women undergoing ovarian cancer surgery: a pilot study. Obstet Gynecol Sci 2017; 60:170–177.
Sakamoto A, Yagi K, Okamura T, et al. Perioperative administration of an intravenous beta-blocker landiolol hydrochloride in patients with lung cancer: a Japanese retrospective exploratory clinical study. Sci Rep 2019; 9:5217.
Ahl R, Matthiessen P, Fang X, et al. Effect of beta-blocker therapy on early mortality after emergency colonic cancer surgery. Br J Surg 2019; 106:477–483.
Yap A, Lopez-Olivo MA, Dubowitz J, et al. Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies. Br J Anaesth 2018; 121:45–57.
Musselman RP, Bennett S, Li W, et al. Association between perioperative beta blocker use and cancer survival following surgical resection. Eur J Surg Oncol 2018; 44:1164–1169.
Thiruvenkatarajan V, Watts R, Calvert M, et al. The effect of esmolol compared to opioids on postoperative nausea and vomiting, postanesthesia care unit discharge time, and analgesia in noncardiac surgery: a meta-analysis. J Anaesthesiol Clin Pharmacol 2017; 33:172–180.
Vahabi S, Rafieian Y, Abbas Zadeh A. The effects of intraoperative esmolol infusion on the postoperative pain and hemodynamic stability after rhinoplasty. J Invest Surg 2018; 31:82–88.
Starr JB, Backonja M, Rozet I. Beta-blocker use is associated with a reduction in opioid use 30 days after total knee arthroplasty. Pain Physician 2019; 22:E395–E406.
De Oliveira GS Jr, Kendall MC, McCarthy RJ. Esmolol does not improve quality of postsurgical recovery after ambulatory hysteroscopy: A prospective, randomized, double-blinded, placebo-controlled, clinical trial. Medicine (Baltimore) 2018; 97:e12647.
Gelineau AM, King MR, Ladha KS, et al. Intraoperative esmolol as an adjunct for perioperative opioid and postoperative pain reduction: a systematic review, meta-analysis, and meta-regression. Anesth Analg 2018; 126:1035–1049.